Cargando…

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine

BACKGROUND: The second generation antipsychotic (SGA) drugs are widely used in psychiatry due to their clinical efficacy and low incidence of neurological side-effects. However, many drugs in this class cause deleterious metabolic side-effects. Animal models accurately predict metabolic side-effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyda, Heidi N., Procyshyn, Ric M., Pang, Catherine C. Y., Hawkes, Erin, Wong, Daniel, Jin, Chen Helen, Honer, William G., Barr, Alasdair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541274/ https://www.ncbi.nlm.nih.gov/pubmed/23326434 http://dx.doi.org/10.1371/journal.pone.0053459

Ejemplares similares

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine
por: Wu, Claire, et al.
Publicado: (2014)

Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance
por: Boyda, Heidi N., et al.
Publicado: (2022)

Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
por: Boyda, Heidi N., et al.
Publicado: (2020)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Association between Serum Lipids and Antipsychotic Response in Schizophrenia
por: Kim, David D., et al.
Publicado: (2019)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
por: Lian, Lulu, et al.
Publicado: (2022)

Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2018)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
por: Yin, John, et al.
Publicado: (2017)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

A Focused Review of the Metabolic Side-Effects of Clozapine
por: Yuen, Jessica W. Y., et al.
Publicado: (2021)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
por: Yuen, Jessica W. Y., et al.
Publicado: (2018)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

A retrospective study of antipsychotic drug switching in a pediatric population
por: Linton, David, et al.
Publicado: (2013)

M216. ASSOCIATIONS OF EXTRAPYRAMIDAL SYMPTOMS WITH PSYCHOTIC SYMPTOMS IN A COHORT OF HOMELESS OR PRECARIOUSLY HOUSED PERSONS WITH OR WITHOUT SCHIZOPHRENIA
por: Kim, David, et al.
Publicado: (2020)

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Ventricular premature contractions associated with iloperidone
por: Achalia, Rashmin, et al.
Publicado: (2013)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia
por: Maitra, Arpita, et al.
Publicado: (2020)

A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents
por: Dodsworth, Thomas, et al.
Publicado: (2018)

Long-term efficacy and safety of iloperidone: an update
por: Rado, Jeffrey T, et al.
Publicado: (2014)

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
por: Johnsen, Erik, et al.
Publicado: (2010)

Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2023)

Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness
por: Lang, Donna J., et al.
Publicado: (2013)

Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine
por: Santarelli, Danielle M., et al.
Publicado: (2013)

Iloperidone-induced Galactorrhea in a Middle-aged Female
por: Dutta, Arghya, et al.
Publicado: (2012)

Iloperidone-induced ejaculatory dysfunction: A case series
por: Ravani, Niraj Narendra, et al.
Publicado: (2016)

White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection
por: Tang, Victor M., et al.
Publicado: (2015)

Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Stability-Indicating Liquid Chromatographic Method for the Quantification of the New Antipsychotic Agent Asenapine in Bulk and in Pharmaceutical Formulation
por: Chhalotiya, Usmangani K., et al.
Publicado: (2012)

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
por: Gonzalez, Jodi M, et al.
Publicado: (2011)

Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early course of schizophrenia: a systematic review and meta-analysis
por: Kim, David D., et al.
Publicado: (2021)

A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study
por: Weiden, Peter J., et al.
Publicado: (2016)

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
por: Tonin, Fernanda S, et al.
Publicado: (2016)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Second-Generation Parenteral Antipsychotic (Olanzapine) as a First-Line Treatment for Acute Undifferentiated Agitation in the Emergency Department in Comparison With Haloperidol
por: Singh, Adheera P, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9kqpoti9rv28f8be9ql79g8k6o